Biocryst Pharmaceuticals (BCRX) Common Equity (2010 - 2026)

Biocryst Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at -$553.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 22.55% year-over-year to -$553.8 million; the trailing twelve-month figure through Mar 2026 stood at -$553.8 million (down 22.55% YoY), and the FY2025 full-year result was -$119.2 million, up 74.96% from the prior year.
• Common Equity for Q1 2026 stood at -$553.8 million, down from -$119.2 million in the prior quarter.
• The five-year high for Common Equity was -$119.2 million in Q4 2025, with the low at -$553.8 million in Q1 2026.
• Historically, Common Equity has averaged -$372.3 million across 5 years, with a median of -$411.0 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity tumbled 175.36% — and 2025, when it surged 74.96%.
• Biocryst Pharmaceuticals' Common Equity stood at -$294.6 million in 2022, then tumbled by 54.63% to -$455.5 million in 2023, then dropped by 4.48% to -$475.9 million in 2024, then surged by 74.96% to -$119.2 million in 2025, then tumbled by 364.82% to -$553.8 million in 2026.
• The last three Common Equity figures came in at -$553.8 million (Q1 2026), -$119.2 million (Q4 2025), and -$387.9 million (Q3 2025), per Business Quant data.